

**FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)**

Oncologic Drugs Advisory Committee (ODAC) Meeting

April 12, 2024

MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

Takyiah Stevenson, PharmD

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Ranjana H. Advani, MD

Saul Rosenberg Professor of Lymphoma Division
of Oncology
Stanford University School of Medicine
Stanford, California

Mark R. Conaway, PhD

Professor
Division of Translational Research and
Applied Statistics
Department of Public Health Sciences
The University of Virginia School of Medicine
Charlottesville, Virginia

Christopher H. Lieu, MD

Associate Professor of Medicine
Associate Director for Clinical Research
Director, Gastrointestinal Medical Oncology
University of Colorado Cancer Center
Aurora, Colorado

Ravi A. Madan, MD

Senior Clinician
Head, Prostate Cancer Clinical Research Section
Genitourinary Malignancies Branch
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

David E. Mitchell

(Consumer Representative)
President
Patients for Affordable Drugs
Bethesda, Maryland

Jorge J. Nieva, MD

Associate Professor of Clinical Medicine
Section Head, Solid Tumors
University of Southern California (USC)
Norris Comprehensive Cancer Center
Keck School of Medicine of USC
Los Angeles, California

Neil Vasan, MD, PhD

Assistant Professor
Division of Hematology & Oncology
Department of Medicine
Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center
New York, New York

**FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)**

Oncologic Drugs Advisory Committee (ODAC) Meeting
April 12, 2024

MEETING ROSTER (cont.)

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Tara Frenkl, MD, MPH

(Industry Representative)

Senior Vice President, Head of Oncology Development
Bayer Pharmaceuticals
Whippany, New Jersey

TEMPORARY MEMBERS (Voting)

Christopher Hourigan, DM, DPhil, FRCP

Director, Virginia Tech Fralin Biomedical
Research Institute (FBRI) Cancer Research Center
Professor, FBRI
Professor, Virginia Tech Carillon
School of Medicine
Washington, District of Columbia

Thomas Martin, MD

Associate Chief, Division of Hematology/Oncology
Helen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, California

Matthew J. Maurer, DMSc

Associate Professor of Biostatistics and Medicine
Division of Clinical Trials and Biostatistics
Division of Hematology
Mayo Clinic
Rochester, Minnesota

Grzegorz (Greg) S. Nowakowski, MD, FASCO

(Acting Chairperson)
Professor of Medicine and Oncology
Deputy Director, Clinical Research
Mayo Clinic Comprehensive Cancer Center
Chair, Lymphoid Malignancy Group
Rochester, Minnesota

Michael A. Riotto

(Patient Representative)

Jamison, Pennsylvania

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director, Oncology Center of Excellence (OCE)
Office of the Commissioner (OC)
Director (Acting)
Office of Oncologic Diseases (OOD)
Office of New Drugs (OND), CDER, FDA

Marc Theoret, MD

Deputy Center Director
OCE, OC
Supervisory Associate Director (Acting)
OOD, OND, CDER, FDA

Nicole Gormley, MD

Associate Director of Oncology Endpoint
Development, OCE
Director, Division of Hematologic
Malignancies II (DHM II)
OOD, OND, CDER, FDA

Bindu Kanapuru, MD

Associate Director of Therapeutic Review
DHM II, OOD, OND, CDER, FDA

**FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)**

Oncologic Drugs Advisory Committee (ODAC) Meeting
April 12, 2024

MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting) (cont.)

Rachel Ershler, MD, MHS

Clinical reviewer
DHM II, OOD, OND, CDER, FDA

Jonathan Vallejo, PhD

Biometrics Team Leader
Division of Biometrics IX (DBIX)
Office of Biostatistics (OB)
Office of Translational Sciences (OTS), CDER, FDA

Jing Zhang, PhD

Statistical Reviewer
DBIX, OB, OTS, CDER, FDA